PATENT CLAIM ANALYSIS

Application Number: 16029131
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-06
Patent Classification: ["514", "249000"]

Abstract:
Described herein are methods and compositions for treating HER2-amplified cancer. The methods include administering to an individual in need thereof ibrutinib.

Claim (Index 6):
The method of  claim 5 , wherein the additional therapeutic agent is an anti-HER2 therapeutic agent, a pan-ErbB inhibitor, or an anti-VEGF therapeutic agent.

Metadata:
- Claim Count in Document: 7.0
- Percentile: 95.0
- Lexical Diversity: 1.09524
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14458157', '15652470', '15198694', '13965135', '14793366']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8225838381913609
- 35 USC 102 Novelty (BERT): 0.7462793246936905
- Combined Prediction Score: 0.8149533868415939
- Mean Citation Score: 660.8564719999998
- Max Citation Score: 844.3267
- Similarity Product: 839.9926427044393

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test